Skip to main content

Advertisement

SpringerLink
Log in

Multimodality approaches to control esophageal cancer: development of chemoradiotherapy, chemotherapy, and immunotherapy

  • Review Article
  • Published:
Esophagus Aims and scope Submit manuscript

Abstract

Esophageal cancer has a poor prognosis despite the fact that surgical techniques have been advanced and optimized, and systemic multimodality approaches have progressed recently. Adding chemotherapy, radiotherapy, and immunotherapy to the basic surgical approach have been shown to have therapeutic benefit for esophageal cancer. This review describes the latest development of chemoradiotherapy, chemotherapy, and immunotherapy, which have contributed to the reduction in esophageal cancer growth and improved the survival of patients. Chemoradiation is a treatment option for resectable esophageal cancer to preserve the esophagus for patients who cannot tolerate surgery. Moreover, a combination of chemoradiotherapy and salvage surgery could extend the survival of patients. The effects of a triplet chemotherapy regimen are currently being verified in some Phase III studies for unresectable advanced/recurrent esophageal cancer. In addition, with the great promise of immune checkpoint inhibitors, strategies that incorporate the use of immunotherapy may shift from the metastatic setting to the neoadjuvant/adjuvant setting as a result of clinical trials. More precise comprehension of the molecular biology of esophageal cancer is expected to further control disease progression using multimodality treatments in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

    PubMed  Google Scholar 

  2. Kitagawa Y, Uno T, Oyama T, et al. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. Esophagus. 2019;16:1–24.

    Article  PubMed  Google Scholar 

  3. Kitagawa Y, Uno T, Oyama T, et al. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 2. Esophagus. 2019;16:25–43.

    Article  PubMed  Google Scholar 

  4. Tanaka Y, Yoshida K, Suetsugu T, et al. Recent advancements in esophageal cancer treatment in Japan. Ann Gastroenterol Surg. 2018;2:253–65.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Seto Y. Essential updates 2018/2019: essential updates for esophageal cancer surgery. Ann GastroenterolSurg. 2020;00:1–5.

    Google Scholar 

  6. Kato H, Sato A, Fukuda H, et al. A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708). Jpn J Clin Oncol. 2009;39(10):638–43.

    Article  PubMed  Google Scholar 

  7. Kato K, Igaki H, Ito Y, et al. Parallel-group controlled trial of esophagectomy versus chemoradiotherapy in patients with clinical stage I esophageal carcinoma (JCOG0502). J Clin Oncol. 2019;37(4 suppl):7.

    Article  Google Scholar 

  8. Nomura M, Kato K, Ando N, et al. Comparison between neoadjuvant chemotherapy followed by surgery and definitive chemoradiotherapy for overall survival in patients with clinical Stage II/III esophageal squamous cell carcinoma (JCOG1406-A). Jpn J Clin Oncol. 2017;47(6):480–6.

    Article  PubMed  Google Scholar 

  9. Kato K, Muro K, Minashi K, et al. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II–III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys. 2011;81:684–90.

    Article  CAS  PubMed  Google Scholar 

  10. Ando N, Kato H, Igaki H, et al. A randomized trial CF postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for clinical stage II/III squamous cell carcinoma of the thoracic esophagus (JCOG 9907). Ann Surg Oncol. 2012;19:68–74.

    Article  PubMed  Google Scholar 

  11. Ito Y, Takeuchi H, Ogawa G, et al. Final analysis of single-arm confirmatory study of definitive chemoradiotherapy including salvage treatment in patients with clinical stage II/III esophageal carcinoma JCOG0909. J Clin Oncol. 2020;38(suppl):4545.

    Article  Google Scholar 

  12. Hironaka S, Komori A, Machida R, et al. The association of primary tumor site with acute adverse event and efficacy of definitive chemoradiotherapy for cStage II/III esophageal cancer: an exploratory analysis of JCOG0909. Esophagus. 2020. https://doi.org/10.1007/s10388-020-00741-w(Online ahead of print).

    Article  PubMed  Google Scholar 

  13. Sudo K, Kato K, Kuwabara H, et al. Patterns of relapse after definitive chemoradiotherapy in Stage II/III (non-T4) esophageal squamous cell carcinoma. Oncology. 2018;94(1):47–544.

    Article  CAS  PubMed  Google Scholar 

  14. Nakamura K, Kato K, Igaki H, et al. Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT Study). Jpn J Clin Oncol. 2013;43(7):752–5.

    Article  PubMed  Google Scholar 

  15. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.

    Article  PubMed  Google Scholar 

  16. Reynolds JV, Preston SR, O'Neill B, et al. ICORG 10–14: NEOadjuvant trial in Adenocarcinoma of the oesophagus and oesophagoGastric junction International Study (Neo-AEGIS). BMC Cancer. 2017;17:401.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.

    Article  CAS  PubMed  Google Scholar 

  18. Hoeppner J, Lordick F, Brunner T, et al. ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvantchemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). BMC Cancer. 2016;16:503.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. Al-Batran S, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948–57.

    Article  PubMed  Google Scholar 

  20. Leong T, Smithers BM, Haustermans K, et al. TOPGEAR: a randomized, phase III trial of perioperative ECF chemotherapy with or without preoperative chemoradiation for resectable gastric cancer: interim results from an international, intergroup trial of the AGITG, TROG, EORTC and CCTG. Ann Surg Oncol. 2017;24:2252–8.

    Article  PubMed  Google Scholar 

  21. A phase III trial evaluating the addition of trastuzumab to trimodality treatment of HER2 overexpressing esophageal adenocarcinoma. Available online: https://clinicaltrials.gov/ct2/show/NCT01196390. Accessed 21 Sept 2020

  22. van Rossum PS, Fried DV, Zhang L, et al. The value of 18F-FDG PET before and after induction chemotherapy for the early prediction of a poor pathologic response to subsequent preoperative chemoradiotherapy in oesophageal adenocarcinoma. Eur J Nucl Med Mol Imaging. 2017;44:71–80.

    Article  PubMed  CAS  Google Scholar 

  23. Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007;8:797–805.

    Article  PubMed  Google Scholar 

  24. zum-Büschenfelde CM, Herrmann K, Schuster T, et al. (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. J Nucl Med. 2011;52:1189–96.

    Article  PubMed  Google Scholar 

  25. PET scan imaging in assessing response in patients with esophageal cancer receiving combination chemotherapy. Cancer and Leukemia Group B trial 80803. Available online: https://clinicaltrials.gov/ct2/show/NCT01333033?term=80803&rank=1. Accessed 21 Sept 2020

  26. Goodman KA, Niedzwiecki D, Hall N, et al. Initial results of CALGB (Alliance): a randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer. J Clin Oncol. 2017;35(4 suppl):1.

    Article  Google Scholar 

  27. Odawara S, Kitajima K, Katsuura T, et al. Tumor response to neoadjuvant chemotherapy in patients with esophageal cancer assessed with CT and FDG-PET/CT—RECIST 1.1 vs PERCIST 1.0. Eur J Radiol. 2018;101:65–71.

    Article  PubMed  Google Scholar 

  28. Ishida K, Ando N, Yamamoto S, et al. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal oncology group (JEOG)/Japan clinical oncology group trial (JCOG9516). Jpn J Clin Oncol. 2004;34(10):615–9.

    Article  PubMed  Google Scholar 

  29. Yokota T, Kato K, Hamamoto Y, et al. Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer. Br J Cancer. 2016;115(11):1328–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Terada M, Hara H, Daiko H, et al. Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE). Jpn J Clin Oncol. 2019;49(11):1055–60.

    Article  PubMed  Google Scholar 

  31. Kataoka K, Tsushima T, Mizusawa J, et al. A randomized controlled Phase III trial comparing 2-weekly docetaxel combined with cisplatin plus fluorouracil (2-weekly DCF) with cisplatin plus fluorouracil (CF) in patients with metastatic or recurrent esophageal cancer: rationale, design and methods of Japan Clinical Oncology Group study JCOG1314 (MIRACLE study). Jpn J Clin Oncol. 2015;45(5):494–8.

    Article  PubMed  Google Scholar 

  32. Hirano H, Kato K. Systemic treatment of advanced esophageal squamous cell carcinoma: chemotherapy, molecular-targeting therapy and immunotherapy. Jpn J Clin Oncol. 2019;49(5):412–20.

    Article  PubMed  Google Scholar 

  33. Petty RD, Dahle-Smith A, Stevenson DAJ, et al. Gefitinib and EGFR gene copy number aberrations in esophageal cancer. J Clin Oncol. 2017;35:2279–87.

    Article  CAS  PubMed  Google Scholar 

  34. Moehler M, Maderer A, Thuss-Patience PC, et al. Cisplatin and 5- fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER). Ann Oncol. 2020;31(2):228–35.

    Article  CAS  PubMed  Google Scholar 

  35. Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996;14:87–96.

    Article  CAS  PubMed  Google Scholar 

  36. Hashimoto H, Abe M, Tokuyama O, et al. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(2):242–9.

    Article  CAS  PubMed  Google Scholar 

  37. Kudo T, Hamamoto Y, Kato K, et al. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. Lancet Oncol. 2017;18:631–9.

    Article  CAS  PubMed  Google Scholar 

  38. Shah MA, Kojima T, Hochhauser D, et al. Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study. JAMA Oncol. 2019;5:546–50.

    Article  PubMed  Google Scholar 

  39. Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:1506–17.

    Article  CAS  PubMed  Google Scholar 

  40. Kojima T, Muro K, Francois E, et al. Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: phase III KEYNOTE-181 study. J Clin Oncol. 2019;37(suppl 4):2.

    Article  Google Scholar 

  41. Metges J, Francois E, Shah M, et al. The phase 3 KEYNOTE-181 study: pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer. Ann Oncol. 2019;30(Supplement 4):iv130.

    Article  Google Scholar 

  42. Kelly RJ, Lockhart AC, Jonker DJ, et al. CheckMate 577: A randomized, double-blind, phase 3 study of adjuvant nivolumab (nivo) or placebo in pts with resected esophageal (E) or gastroesophageal junction (GEJ) cancer. J Clin Oncol. 2017;35(suppl):TPS4131.

    Article  Google Scholar 

  43. An investigational immuno-therapy study of nivolumab or placebo in patients with resected esophageal or gastroesophageal junction cancer. Available online: https://ClinicalTrials.gov/show/NCT02743494. Accessed 21 Sept 2020

  44. Ajani JA, Kato K, Doki Y, et al. CheckMate 648: A randomized phase 3 study of nivolumab plus ipilimumab or nivolumab combined with fluorouracil plus cisplatin versus fluorouracil plus cisplatin in patients with unresectable advanced, recurrent, or metastatic previously untreated esophageal squamous cell carcinoma. J Clin Oncol. 2018;36:TPS193.

    Article  Google Scholar 

  45. A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin. Available online: https://ClinicalTrials.gov/show/NCT03143153. Accessed 21 Sept 2020

  46. Kato K, Shah MA, Enzinger P, et al. KEYNOTE-590: phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. Future Oncol. 2019;15(10):1057–66.

    Article  CAS  PubMed  Google Scholar 

  47. First-line Esophageal Carcinoma Study With Chemo vs. Chemo PlusPembrolizumab (MK-3475–590/KEYNOTE-590). https://ClinicalTrials.gov/show/NCT03189719. Accessed 21 Sept 2020

  48. Ohigashi Y, Sho M, Yamada Y, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res. 2005;11:2947–53.

    Article  CAS  PubMed  Google Scholar 

  49. Derks S, Nason KS, Liao X, et al. Epithelial PD-L2 expression marks barrett'sesophagus and esophageal adenocarcinoma. Cancer Immunol Res. 2015;3:1123–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Mimura K, Yamada L, Ujiie D, et al. Immunotherapy for esophageal squamous cell carcinoma: a review. Fukushima J Med Sci. 2018;64(2):46–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2002;2:277–88.

    Article  CAS  PubMed  Google Scholar 

  52. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267:1456–62.

    Article  CAS  PubMed  Google Scholar 

  53. Suzuki Y, Mimura K, Yoshimoto Y, et al. Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Res. 2012;72:3967–76.

    Article  CAS  PubMed  Google Scholar 

  54. Kelly RJ, Zaidi AH, Smith MA, et al. The dynamic and transient immune microenvironment in locally advanced esophageal adenocarcinoma post chemoradiation. Ann Surg. 2018;268(6):992–9.

    Article  PubMed  Google Scholar 

  55. Huang J, Jianming X, Chen Y, et al. Camrelizumab versus investigator’s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, Phase 3 study. Lancet Oncol. 2020;21(6):832–42.

    Article  CAS  PubMed  Google Scholar 

  56. Study of camrelizumab (SHR-1210) in combination with concurrent chemoradiotherapy in locally advanced esophageal cancer. Available online:https://clinicaltrials.gov/ct2/show/NCT04426955. Accessed 21 Sept 2020

  57. Study of SHR-1210 in combination with chemotherapy in advanced esophageal cancer. Available online: https://clinicaltrials.gov/ct2/show/NCT03691090. Accessed 21 Sept 2020

  58. Study of tislelizumab (BGB-A317) versus placebo in combination with chemoradiotherapy in patient with ESCC. Available online: https://clinicaltrials.gov/ct2/show/NCT03957590. Accessed 21 Sept 2020

  59. A study of tislelizumab (BGB-A317) versus chemotherapy as second line treatment in participants with advanced esophageal squamous cell carcinoma. Available online: https://clinicaltrials.gov/ct2/show/NCT03430843. Accessed 21 Sept 2020

  60. A study of tislelizumab (BGB-A317) in combination with chemotherapy as first line treatment in participants with advanced esophageal squamous cell carcinoma. Available online: https://clinicaltrials.gov/ct2/show/NCT03783442. Accessed 21 Sept 2020

  61. Mamdani H, Schneider BJ, Kasi PM, et al. Safety and efficacy of durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: two-year follow-up results from Big Ten Cancer Research Consortium study. J Clin Oncol. 2020;38(suppl 4):404.

    Article  Google Scholar 

  62. Stagg J, Loi S, Divisekera U, et al. Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137mAb therapy. Proc Natl Acad Sci U S A. 2011;108(17):7142–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Gall VA, Philips AV, Na Qiao N, et al. Trastuzumab increases HER2 uptake and cross-presentation by dendritic cells. Cancer Res. 2017;77(19):5374–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Janjigian YY, Maron SB, Chatila WK, et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2020;21(6):821–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Chung H, Bang Y, Fuchs C, et al. KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapyforHER2+ metastatic gastric or gastroesophageal junction cancer: a double-blind, randomized, placebo-controlled phase 3 study. Ann Oncol. 2019;30(suppl 4):iv25.

    Article  Google Scholar 

  66. Pembrolizumab/placebo plus trastuzumab plus chemotherapy in human epidermal growth factor receptor 2 positive (HER2+) advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma (MK-3475–811/KEYNOTE-811). Available online: https://clinicaltrials.gov/ct2/show/NCT03615326. Accessed 21 Sept 2020

Download references

Author information

Authors and Affiliations

  1. Division of Gastrointestinal Surgery, Department of Surgery, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan

    Yoshihiro Kakeji, Taro Oshikiri, Gosuke Takiguchi, Shingo Kanaji, Takeru Matsuda, Tetsu Nakamura & Satoshi Suzuki

Authors
  1. Yoshihiro Kakeji
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Taro Oshikiri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gosuke Takiguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shingo Kanaji
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takeru Matsuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tetsu Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Satoshi Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoshihiro Kakeji.

Ethics declarations

Ethical Statement

Each treatment modality should be offered with enough informed consent.

Conflict of interest

None of the authors have any commercial sponsorship to disclose regarding this research.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kakeji, Y., Oshikiri, T., Takiguchi, G. et al. Multimodality approaches to control esophageal cancer: development of chemoradiotherapy, chemotherapy, and immunotherapy. Esophagus 18, 25–32 (2021). https://doi.org/10.1007/s10388-020-00782-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10388-020-00782-1

Keywords

Search

Navigation